<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980561</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00089933</org_study_id>
    <nct_id>NCT03980561</nct_id>
  </id_info>
  <brief_title>UH3 Varenicline for Cannabis Use Disorder</brief_title>
  <official_title>Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marijuana is the most commonly used illicit drug. There is high demand for effective&#xD;
      interventions for cannabis use disorder, yet few specific treatments for have been developed.&#xD;
      This study will evaluate the efficacy of varenicline for reducing marijuana use in people who&#xD;
      use marijuana frequently.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of varenicline, compared with placebo, for reducing cannabis use: total number of use sessions at each weekly visit</measure>
    <time_frame>Treatment phase Weeks 6-12</time_frame>
    <description>Cannabis use reduction as measured by daily substance use logs and examined as the total number of use sessions at each weekly visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of varenicline, compared with placebo, when used for cannabis use disorder: frequency of treatment-emergent AEs</measure>
    <time_frame>12 weeks (across the active treatment period)</time_frame>
    <description>Comparing the frequency of treatment-emergent AEs between treatment groups. Of particular interest will be AEs leading to medication discontinuation and the occurrence of treatment-related serious AEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Active medication</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix, Apo-Varenicline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive medication</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days&#xD;
             per week in the last 30 days.&#xD;
&#xD;
          -  Express interest in receiving treatment for cannabis use disorder and reducing use.&#xD;
&#xD;
          -  Must be at least 18 years of age.&#xD;
&#xD;
          -  If female and of childbearing potential, must agree to use acceptable methods of birth&#xD;
             control for the duration of the trial.&#xD;
&#xD;
          -  Must consent to random assignment, and be willing to commit to medication ingestion.&#xD;
&#xD;
          -  Must be able to read and provide informed consent.&#xD;
&#xD;
          -  Must have body weight &gt;110lbs (50kg) and have BMI between 18 and 35kg/m2&#xD;
&#xD;
          -  Must function at an intellectual level and have knowledge of the English language to&#xD;
             sufficiently allow for accurate completion of assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, nursing, or plan to become pregnant during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Individuals with severe renal impairment (creatinine clearance less than 30 mL per&#xD;
             minute).&#xD;
&#xD;
          -  Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic&#xD;
             disorder. Stably treated MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia&#xD;
             diagnoses are acceptable (i.e. same dose of medication has been prescribed for at&#xD;
             least 2 months prior to screening and no changes in current medication expected during&#xD;
             course of the trial).&#xD;
&#xD;
          -  Past year or current posttraumatic stress disorder.&#xD;
&#xD;
          -  Subjects who are actively suicidal, or who report suicidal ideation (SI) with intent&#xD;
             or plan in the past year.&#xD;
&#xD;
          -  Subjects who have a SBQ R total score â‰¥8, or for whom the investigator judges that a&#xD;
             risk assessment by a qualified medical professional is required. Subjects answering&#xD;
             'yes' on questions 4 or 5 of C-SSRS will be referred to assessment by a qualified&#xD;
             mental health professional.&#xD;
&#xD;
          -  Suicidal behavior within the past 10 years or a lifetime history of serious or&#xD;
             recurrent suicidal behavior.&#xD;
&#xD;
          -  Concomitant use of psychotropic medications, with the exception of stable doses&#xD;
             (defined as no dosing adjustments in the past two months) of non-MAO-I&#xD;
             antidepressants, non-benzodiazepine anxiolytics, and ADHD medications.&#xD;
&#xD;
          -  Current use of medications prescribed for mania or psychosis.&#xD;
&#xD;
          -  Current use of buproprion or nortryptiline.&#xD;
&#xD;
          -  Moderate or severe non-cannabis substance use disorders within the past 60 days with&#xD;
             the exception of tobacco use disorder.&#xD;
&#xD;
          -  Past year or current moderate or severe alcohol use disorder.&#xD;
&#xD;
          -  Individuals taking an investigational agent within the last 30 days before baseline&#xD;
             visit.&#xD;
&#xD;
          -  Individuals with clinically significant medical disorders or lab abnormalities.&#xD;
&#xD;
          -  Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the&#xD;
             upper limit of normal and/or total bilirubin greater than two times the upper limit of&#xD;
             normal.&#xD;
&#xD;
          -  Individuals with clinically significant cardiovascular disease in the past 6 months&#xD;
             (e.g., myocardial infarction, CABG, PTCA, severe or unstable angina, serious&#xD;
             arrhythmia, or any clinically significant ECG conduction abnormality.&#xD;
&#xD;
          -  Individuals with clinically significant cerebrovascular disease in the past 6 months&#xD;
             such as TIA, CVA, or stroke.&#xD;
&#xD;
          -  Hypersensitivity to varenicline.&#xD;
&#xD;
          -  Individuals who have participated in the clinical trial of any investigative compound&#xD;
             within the last 60 days&#xD;
&#xD;
          -  Individuals who are on probation or under a mandate to obtain treatment.&#xD;
&#xD;
          -  Individuals with plans to initiate or change frequency of attendance at self-help&#xD;
             meetings (e.g. AA, NA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Wagner, MA, LPC</last_name>
    <phone>843-792-0484</phone>
    <email>wagne@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Nunn, MS</last_name>
    <phone>843-792-0476</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Wagner, MA, LPC</last_name>
      <phone>843-792-0484</phone>
      <email>wagne@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Services of Pickens County</name>
      <address>
        <city>Pickens</city>
        <state>South Carolina</state>
        <zip>29671</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Chapman, MA, LPC, LAC, AADC</last_name>
      <phone>864-898-2992</phone>
      <email>chapmanb@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>marijuana</keyword>
  <keyword>substance use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

